Why the study?
Does iron therapy improve outcomes in patients with heart failure and iron deficiency?
Does iron therapy improve outcomes in patients with heart failure and iron deficiency?
Intravenous iron supplementation, specifically ferric carboxymaltose, is recommended for symptomatic patients with heart failure with reduced ejection fraction and iron deficiency, while oral iron is ineffective.
Answers are grounded in this paper and cite their sources.
Supports IV iron repletion in symptomatic HFrEF with iron deficiency; leaves open effects on hard clinical outcomes.
In patients with heart failure (HF), iron deficiency (ID) correlates with decreased exercise capacity and poor health-related quality of life, and predicts worse outcomes. Both absolute (depleted iron stores) and functional (where iron is unavailable for dedicated tissues) ID can be easily evaluated in patients with HF using standard laboratory tests (assessment of serum ferritin and transferrin saturation). Intravenous iron therapy in iron-deficient patients with HF and reduced ejection fraction has been shown to alleviate HF symptoms and improve exercise capacity and quality of life. In this paper, we provide information on how to diagnose ID in HF. Further we discuss pros and cons of different iron preparations and discuss the results of major trials implementing iron supplementation in HF patients, in order to provide practical guidance for clinicians on how to manage ID in patients with HF.
No takes yet. Share an insight, caveat, or question.
Drozd et al. (2016) conducted a review in Heart failure and iron deficiency. Intravenous iron therapy (ferric carboxymaltose) vs. Oral iron or placebo was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: